Telix ARTMS, Inc. (ARTMS), a global leader in radioisotope production technologies, is pleased to announce that the drug ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection) for use in patients with prostate cancer.

According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.

Gozellix®, after radiolabeling with 68Ga, is indicated for PET Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory ...

The PDUFA date is August 27, 2025.

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Updated biographies for board candidates at the upcoming Annual General Meeting ...

The FDA has expanded Pluvicto's indication for PSMA-positive mCRPC patients post-ARPI therapy, delaying taxane-based chemotherapy. Selection for Pluvicto should be based on PSMA expression using ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo. The Food and Drug Administration (FDA) has approved Cabometyx ® (cabozantinib ...

MRI utilization for prostate cancer diagnosis increased significantly from 2012 to 2019, with a notable rise among older patients. Racial disparities in MRI use have decreased, but urban-rural and ...